These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 18718641

  • 21. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC.
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [Abstract] [Full Text] [Related]

  • 22. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group.
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [Abstract] [Full Text] [Related]

  • 23. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V.
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [Abstract] [Full Text] [Related]

  • 24. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 27. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN.
    BJU Int; 2012 Jan 01; 109(2):183-8. PubMed ID: 21992404
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L.
    J Clin Endocrinol Metab; 1989 Feb 01; 68(2):461-8. PubMed ID: 2465302
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.
    Eur Urol; 2008 Feb 01; 53(2):244-52. PubMed ID: 18006217
    [Abstract] [Full Text] [Related]

  • 35. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G, Rittmaster RS, Klocker H.
    Urologe A; 2002 Sep 01; 41(5):412-24. PubMed ID: 12426858
    [Abstract] [Full Text] [Related]

  • 36. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.
    J Urol; 2011 Jul 01; 186(1):191-7. PubMed ID: 21575967
    [Abstract] [Full Text] [Related]

  • 37. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Brown CT, Nuttall MC.
    Int J Clin Pract; 2003 Oct 01; 57(8):705-9. PubMed ID: 14627182
    [Abstract] [Full Text] [Related]

  • 38. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.
    Kravchick S, Cytron S, Mamonov A, Peled R, Linov L.
    Urology; 2009 Jun 01; 73(6):1274-8. PubMed ID: 19375786
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia].
    Tsukamoto T, Shirai T, Sakamoto S, Akiyama A, Takeuchi H, Yajima M, Terao T, Endo Y.
    Hinyokika Kiyo; 2010 Dec 01; 56(12):677-82. PubMed ID: 21273805
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.